Sanofi lifts profit outlook as Dupixent sales surge 43%
Reuters
Published Jul 28, 2022 01:33AM ET
Updated Jul 28, 2022 02:26AM ET
By Ludwig Burger
(Reuters) -French healthcare group Sanofi (NASDAQ:SNY) lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.
In a statement on Thursday, Sanofi said it now expects 2022 adjusted earnings per share to grow by about 15%, excluding the effect of currency swings. It had previously predicted low double-digit percentage growth.
Sanofi's second-quarter business operating income, or adjusted earnings before interest and tax, rose 21.5% to 2.75 billion euros ($2.81 billion), surpassing the average analyst estimate of 2.66 billion euros posted on the company's website.
In March the French group said peak annual sales of Dupixent, jointly developed with Regeneron (NASDAQ:REGN), would be more than 13 billion euros, up from a previous target of more than 10 billion euros.
Revenue from anti-inflammatory treatment Dupixent jumped 43.4% to 1.96 billion euros in the reported quarter, beating an analyst consensus of 1.86 billion euros, on prescriptions in dermatitis, asthma and certain nasal infections.
The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked up on cough an cold remedies during an upswing in COVID-19 infections.
Finance chief Jean-Baptiste de Chatillon told reporters the business, which includes parts acquired from Boehringer Ingelheim, was making further progress under a 2019 plan to become a standalone business.
But the CFO said there were no conclusions to be drawn from the separate listing this month and underwhelming market value of OTC group Haleon, previously owned by GSK and Pfizer (NYSE:PFE).
He added that Sanofi and development partner GSK were still waiting to hear back from regulators on their protein-based COVID-19 vaccine candidate, modelled on the Beta variant.
The partners set out to help to fight the pandemic but they do not see it as a major economic opportunity, he said. "That has not changed from the beginning," he added.
Get The News You Want
($1 = 0.9800 euros)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.